This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
1 Citations 1 Q&As
1 Citations
Facts about Ribosomal protein S6 kinase beta-1.
Upon mitogenic stimulation, phosphorylation by the mammalian target of rapamycin complex 1 (mTORC1) leads to dissociation in the EIF3 complex and activation. The active form then phosphorylates and activates several substrates from the pre-initiation complex, including the EIF2B complex and the cap-binding complex component EIF4B.
Human | |
---|---|
Gene Name: | RPS6KB1 |
Uniprot: | P23443 |
Entrez: | 6198 |
Belongs to: |
---|
protein kinase superfamily |
EC 2.7.11; EC 2.7.11.1; p70 ribosomal S6 kinase alpha; p70 S6 kinase alpha; p70 S6 Kinase; p70 S6 kinase, alpha 1,70 kDa ribosomal protein S6 kinase 1; p70 S6 kinase, alpha 2; p70 S6KA; p70 S6K-alpha; p70(S6K)-alpha; p70-alpha; p70-S6K; P70S6K1; PS6K; ribosomal protein S6 kinase beta-1; Ribosomal protein S6 kinase I; ribosomal protein S6 kinase, 70kD, polypeptide 1; ribosomal protein S6 kinase, 70kDa, polypeptide 1; RPS6KB1; S6K; S6K1; S6K1p70-S6K 1; S6K-beta-1; serine/threonine kinase 14 alpha; Serine/threonine-protein kinase 14A; STK14A
Mass (kDA):
59.14 kDA
Human | |
---|---|
Location: | 17q23.1 |
Sequence: | 17; NC_000017.11 (59893046..59950574) |
Widely expressed.
Cell junction, synapse, synaptosome. Mitochondrion outer membrane. Mitochondrion. Colocalizes with URI1 at mitochondrion.; [Isoform Alpha I]: Nucleus. Cytoplasm.; [Isoform Alpha II]: Cytoplasm.
This article will give you more information about RPS6KB1's marker. You'll also learn how PPP1CC dephosphorylates RPS6KB1 and how MiR-195 binds to this molecule. You'll also learn how ELISA kits can achieve picogram-level sensitivity, and the best IHC applications.
Baculovirus expression systems containing His-Tag produce the RPS6KB1 gene marker. The protein contains sequence domains from 1 to 525 aa, making it suitable for SDS-PAGE applications. The protein can be stored at 2 to 8 degrees Celsius for a week. Aliquots can also be stored at temperatures between -20 and 80 degrees Celsius for longer-term storage. All researchers around the globe have access to product credits.
The RPS6KB1 marker is a widely-used molecule in immunohistochemistry. This method uses antibody/antigen interactions to visualize the distribution and localization of specific cellular components. To improve this process, researchers optimized sample preparation and staining. This is a strong signal that can easily be understood. In order to maximize the value of this reagent, Boster Bio provides a detailed reference guide for users.
Multiple studies have shown that miR195 binds RPS6, an important player in cancer development. Additionally, circAGFG1, the cellular regulator that promotes metastasis, inhibits cell proliferation and is a cellular controller of cell proliferation. This study revealed that circAGFG1 acts in a sponge role for miR-195-5p which relieves microRNA repression of CCNE1. These changes were reversed in TNBC-cells by miR195-5p mimics as well as inhibitors. These results suggest that TNBC is a strong prognosticator, and that circAGFG1 could be an important marker for diagnosis or therapy.
The miR-195-RPS6KB1 axis partially explains the molecular mechanism of prostate cancer development and represents a new therapeutic target for treatment of the disease. The American Association for Cancer Research supports these findings and plans to publish them in Nature. However, there are important limitations to the axis. For patients with adriamycinresistant prostate cancer, it may not work.
Besides the binding of miR-195 to RPS6KB1, miR-16 is known to promote apoptosis in tumor cells by suppressing PD-L1 expression. By enhancing T cell responses to the tumor microenvironment, miR-16 or miR-195 can enhance radiotherapy's effectiveness. However, miR-16/miR-195 are not directly associated with cancer progression.
Additionally, miR195 inhibits CCNE1 transcription, which may play a role in the resistance of glioma cell lines to TMZ chemotherapy. Further research is needed to understand the role of miR-195 in glioma cells, and its potential clinical application. The National Natural Science Foundation of China, Pengzhou Kong and Pengzhou Kong supported this study. The authors declare there are no conflicts of interests.
ELISA kits that have been designed to detect HIV antibodies at the picogram level have improved significantly in sensitivity and reproducibility. The improved sensitivity levels are attributed to new methods of immunoassay optimization. These methods include the use of gold nanoparticles to improve sensitivity and optimize immunoassay parameters. In some cases, these techniques are also capable of detecting the smallest amounts of HIV antibodies.
Enzyme-linked immunosorbent asays (ELISAs), can be used to detect proteins in plasma and serum. They are highly reproducible and require very little hands-on time. ELISA Kits have a picogram sensitivity that can detect infectious diseases and cytokines. They are easy-to-use and produce quantitative information.
In some cases, ELISA kits' sensitivity can be increased to sub-nanogram level. This is especially useful for screening protein targets or quantifying protein expression under different conditions. Some ELISA products are also equipped with monoclonal antibodies that increase sensitivity while reducing background noise. These antibodies are combined with polyclonal IgYs that can be used as detection and capture antibodies. ELISA kits can also reach picogram level sensitivity using this method.
PicokineTM technology can also be used to enhance the capture of antibodies. Picokine (tm) technology improves the binding efficiency and reduces non-specific binding. This allows ELISA to achieve picogram level sensitivity as well as high specificity. They can detect many proteins and antigens. They are widely available and have been thoroughly tested.
Before purchasing the marker needed for IHC studies you should carefully read the label. This document should clearly define the product's purpose, dilution requirements, and recommended sample handling. It should also provide guidance for tissue checks to ensure stability of IHC devices. It should also include written quality control criteria to ensure consistency of the primary antibody-reagent product across production lots.
The immunohistochemical analyses of primary PDACs and metastatic liver metastases were performed. Twenty-nine proteins were identified using the STRING database, including SMAD4, p53, and CEACAM1. These markers were then subjected to IHC. The study revealed a strong correlation between protein loss and the presence or absence of tumours. The markers were found to be associated with heterozygotes and homozygotes. Twenty-one% of all study cases showed loss in the protein in both primary or metastatic lesions. Patients with retained SMAD4 expression were similar in appearance to patients with nonglandular lesions.
IHC requires biopsies. The tissue is processed using a microtome. After that, it is incubated by the appropriate antibodies. Fluorescent markers are used to visualize the binding site of the antibody. Some of these fluorescent markers are linked to the primary antibody or the secondary antibody. IHC is an invaluable tool for tumor research if the antibodies can be used in combination with the tissue. This marker can also help to identify the tumor markers.
The RPS6KB1 antibody manufacturer provides specific reagents for this protein. The antibodies have been thoroughly tested for multiple purposes and are supported by solid technical support. Excellent customer service is also provided by the PS6K anti-microbial reagents manufacturer. This marker is excellent for IHC. IHC can now be performed with the help PS6K antibody.
Secondary antibodies may be fluorescent or chemically luminescent. They are used to detect target antigens in various applications, including immunohistochemistry, western blotting, and flow cytometry. Secondary antibodies may also be used in multiplexing, multi-labeling, and other experiments depending on their application. These are some examples of secondary antibodies that have been applied to the RPS6KB1 Marker.
The primary antibody should also be diluted 1X in TBST containing bovine serum albumin or 5% nonfat dried milk. The secondary antibody can be conjugated with a wide range of labels. It is crucial to choose the right secondary antibody for your results. A commercially available RPS6KB1-labeled antigen is the best way to determine the quality and reproducibility of secondary antibodies.
Secondary antibody applications to the RPS6KB1. The antibodies used to detect this recombinant proteins are currently made from affinity purification of human antibody. They are able to detect the phosphorylated Protein (p-S6). You can also use the antibodies to identify various other cancer proteins. These include RPS6KB1, R6 and PKM2.
Despite the many applications of this marker in cancer research, more research is needed to determine its role in various types of cancer. It is believed that the protein p-RPS6KB1 has a role in NSCLC and other cancers. RPS6KB1 in normal lung tissue is negative, while it is positive in lung cancer. The protein is expressed in all types tumors but is most commonly found in NSCLC.
LY2584702 inhibits cell proliferation in A549 cells. The effects increase with increasing concentration and time. The drug inhibited the growth of A549 cells at 0.2 mM. However, statistically, the effects were not significant. The effects of ly2584702 however were less evident on the SK–MES-1-cell line, but the inhibitory action on RPS6KB1-cell proliferation was significantly more.
PMID: 1922062 by Grove J., et al. Cloning and expression of two human p70 S6 kinase polypeptides differing only at their amino termini.
PMID: 9804755 by Gout I., et al. Molecular cloning and characterization of a novel p70 S6 kinase, p70 S6 kinase beta containing a proline-rich region.
*More publications can be found for each product on its corresponding product page